How do I buy Xenon Pharmaceuticals Inc (XENE) stock?

Buying Xenon Pharmaceuticals Inc (XENE) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "XENE", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy XENE by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for XENE on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Xenon Pharmaceuticals Inc from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Xenon Pharmaceuticals Inc (XENE) pay dividends?

At the moment, Xenon Pharmaceuticals Inc (XENE) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track XENE's performance via the price chart in the Gotrade app.

Is buying XENE on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy XENE?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if XENE is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Xenon Pharmaceuticals Inc (XENE) Stock Price: Nov 11 Close $42.10

Latest news

Zacks Investment Research

Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review

PositiveXENESeptember 27, 2026

MarketBeatPositive

Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review

XENE

Business Wire

XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

NeutralXENESeptember 23, 2026

Business WireNeutral

XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

XENE

Proactive Investors

Xenon Pharmaceuticals falls 30% after depression trial enrollment pause

NegativeXENESeptember 18, 2026

Proactive InvestorsNegative

Xenon Pharmaceuticals falls 30% after depression trial enrollment pause

XENE

Zacks Investment Research

XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback

NegativeXENESeptember 18, 2026

Zacks Investment ResearchNegative

XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback

XENE

Investors Business Daily

The Biotech Surged 50% On Positive Data In March. Now, It's Almost Gone.

NeutralXENESeptember 18, 2026

Investors Business DailyNeutral

The Biotech Surged 50% On Positive Data In March. Now, It's Almost Gone.

XENE

Reuters

Xenon pauses new enrollment in depression, bipolar disorder trials over side-effect concerns

XENESeptember 17, 2026

Reuters

Xenon pauses new enrollment in depression, bipolar disorder trials over side-effect concerns

XENE

Investors Business Daily

Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback

XENESeptember 10, 2026

Investors Business Daily

Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback

XENE

MarketBeat

Xenon Pharmaceuticals Q2 Earnings Call Highlights

XENEAugust 7, 2026

MarketBeat

Xenon Pharmaceuticals Q2 Earnings Call Highlights

XENE

News tone: automated (AI) classification of the article's content, not a price prediction.

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

SectorHealthcare

IndustryBiotechnology

Employees358

CEOMr. Ian C. Mortimer C.M.A., CPA, M.B.A.

IPO DateOct 17, 2014

HeadquartersBurnaby, BC

Key Executives

Name	Title	Year Born
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.	President, CEO & Director	1976
Mr. Thomas Patrick Kelly J.D.	Chief Financial Officer	1971
Dr. Matthew D. Ronsheim Ph.D.	Chief Operating Officer	1972
Ms. Andrea DiFabio J.D.	Chief Legal Officer & Corporate Secretary	1968
Dr. Christopher John Kenney M.D.	Chief Medical Officer	1971
Mr. Darren S. Cline M.B.A.	Chief Commercial Officer	1964
Ms. Shelley McCloskey B.A.	Executive Vice President of Human Resources	1960
Dr. Robin P. Sherrington Ph.D.	Executive Vice President of Strategy & Innovation	1961
Dr. James R. Empfield Ph.D.	Executive Vice President of Drug Discovery	1961
Ms. Colleen Alabiso	Senior Vice President of Corporate Affairs	—

Fundamentals

Valuation

Price-to-sales ratio542.40

Price-to-book value3.55

PEG ratio-0.06

Profitability

Return on Equity-44.00%

Return on Assets-42.00%

EBITDA$-407.41M

Trading

Average volume1,325,184

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 62.71
MACD 12/26/9: 0.05
EMA 9 of MACD: -1.01
MACD histogram: 1.07
SMA 50: $41.91; Price above SMA 50
EMA 50: $42.33; Price below EMA 50
SMA 200: $52.29; Price below SMA 200
EMA 200: $47.98; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

7 analyst ratings

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Buy

86% Buy

14% Hold

0% Sell

Analyst price target

Low: $46.00
Average: $65.43
High: $90.00

Deutsche Bank

David Hoang

Hold

Target price

$46.00

Needham

Serge Belanger

Buy

Target price

$60.00

Wells Fargo

Benjamin Burnett

Buy

Target price

$64.00

Wedbush

Laura Chico

Buy

Target price

$55.00

Baird

Brian Skorney

Buy

Target price

$90.00

RBC Capital

Brian Abrahams

Buy

Target price

$70.00

Guggenheim

Delma Caiati

Buy

Target price

$73.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-15.7	+20.9
2022	-14.2	+7.0	-3.7	-12.6	-9.3	+14.0	+7.7	+22.5	-8.7	+1.5	-0.6	+6.8
2023	+4.9	+0.7	-11.3	+9.8	-3.6	-0.4	-3.5	+4.3	-14.0	-6.2	+17.2	+25.2
2024	+0.7	+1.7	-8.1	-3.5	-10.4	+1.4	+14.4	-7.8	-1.9	+1.8	+2.3	-6.9
2025	-0.5	-6.4	-6.3	+24.7	-24.3	+4.1	-4.8	+26.9	+2.2	+7.2	+8.8	+3.0
2026	-7.8	+4.3	+36.7	-1.1	-2.5	+13.0	+3.9	-3.3	-38.0	-3.9	+11.9

Compare stocks

XENE

Buy XENE

Market cap

$4.14B

-

Price / Earnings ratio

-9.50

-

Price / Sales ratio

542.40

-

Dividend yield

0.00%

-

Average volume

1,325,184

-

Earnings per share

$-4.70

-

Xenon Pharmaceuticals Inc (XENE) Stock

Key stats

Compare with XENE

Recent news

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?

Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month

Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month

Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review

Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review

XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?

Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month

Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month

Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review

Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review

XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

Xenon Pharmaceuticals falls 30% after depression trial enrollment pause

Xenon Pharmaceuticals falls 30% after depression trial enrollment pause

XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback

XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback

The Biotech Surged 50% On Positive Data In March. Now, It's Almost Gone.

The Biotech Surged 50% On Positive Data In March. Now, It's Almost Gone.

Xenon pauses new enrollment in depression, bipolar disorder trials over side-effect concerns

Xenon pauses new enrollment in depression, bipolar disorder trials over side-effect concerns

Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback

Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback

Xenon Pharmaceuticals Q2 Earnings Call Highlights

Xenon Pharmaceuticals Q2 Earnings Call Highlights

About Xenon Pharmaceuticals Inc

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade